第22回先端研究セミナーのお知らせ

演題：Pharmacologic Manipulation of Stem Cells and Cancer Stem Cells

演者：Michael Kahn, Ph.D (Norris Comprehensive Cancer Center, University of Southern California)

抄録：

The ultimate decisions for a stem cell (normal or cancerous) involve remaining quiescent or to initiate differentiation. We propose that essentially all cellular information – i.e. from other signaling pathways, nutrient levels, etc. – is funneled down into a choice of coactivator usage, either CBP or p300, by their interacting partner beta-catenin (or catenin-like molecules in the absence of beta-catenin) to make the critical decision to either remain quiescent, or once entering cycle to divide symmetrically or asymmetrically.  Based upon this work, the clinical candidate PRI-724 was developed and is presently undergoing multiple Phase I/II clinical trials for oncology. This extremely fundamental decision process can now be safely controlled pharmacologically in vivo. The ability to regulate this decision has major implications for novel therapies for disease, which will be discussed.

日時：２０１４年２月２４日（月）　１１：００〜１２：００

場所：研究所1F セミナー室B

連絡先：清宮啓之（内線5491）

＊外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、 医学・生物分野の研究に携わる方を対象としております。